Sciwind said it has licensed its GLP-1 obesity drug ecnoglutide to Pfizer and Verdiva Bio, while indicating it remains open to additional partners for the remaining rights it holds. The company’s update frames ecnoglutide’s commercialization as still expanding beyond the existing bilateral licensing arrangements. For the market, the approach highlights how Chinese GLP-1 developers continue to structure multi-territory deals to maximize development and commercialization leverage as competition intensifies among GLP-1 and next-generation obesity programs.